Parathyroid scintigraphy in renal hyperparathyroidism: The added diagnostic value of SPECT and SPECT/CT

David Taïeb, Pablo Ureña-Torres, Paolo Zanotti-Fregonara, Domenico Rubello, Alice Ferretti, Ioline Henter, Jean François Henry, Francesca Schiavi, Giuseppe Opocher, Johan G. Blickman, Patrick M. Colletti, Elif Hindié

Research output: Contribution to journalArticlepeer-review

Abstract

Secondary hyperparathyroidism (sHPT) is a major complication for patients with end-stage renal disease on long-term hemodialysis or peritoneal dialysis. When the disease is resistant to medical treatment, patients with severe sHPT are typically referred for parathyroidectomy (PTx), which usually improves biological parameters as well as clinical signs and symptoms. Unfortunately, early surgical failure with persistent disease may occur in 5%-10% of patients and recurrence reaches 20%-30% at 5 years. Presently, the use of parathyroid scintigraphy in sHPT is usually limited to the management of surgical failures after initial PTx. This review describes the strengths and limitations of typical 99mTc-sestamibi imaging protocols, and highlights the potential benefits of using parathyroid scintigraphy in the initial workup of surgical patients.

Original languageEnglish
Pages (from-to)630-635
Number of pages6
JournalClinical Nuclear Medicine
Volume38
Issue number8
DOIs
Publication statusPublished - Aug 2013

Keywords

  • Tc-MIBI
  • dual isotope
  • hemodialysis
  • parathyroid scintigraphy
  • secondary hyperparathyroidism
  • surgery
  • tertiary hyperparathyroidism

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Parathyroid scintigraphy in renal hyperparathyroidism: The added diagnostic value of SPECT and SPECT/CT'. Together they form a unique fingerprint.

Cite this